# US 9,750,789 B2 · Use of matrix metalloproteinase inhibitors to treat tuberculosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,750,789 B2
- Document ID: US9750789B2
- Status: Granted
- Kind: B2
- Application number: 14/000,134
- Filed: 2012-02-17
- Published: 2014-07-17
- Granted: 2017-09-05
- Earliest claimed: 2011-02-18
- Assignees: The Trustees of Columbia University in the City of New York
- Applicants: Jeanine D'armiento; Paul Elkington; Jon S. Friedland
- Inventors: Jeanine D'armiento; Paul Elkington; Jon S. Friedland
- Web page: https://patentgrep.com/patent/US9750789B2

## CPC

- A61K 38/55: Protease inhibitors
- A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/65: Tetracyclines
- A61K 38/4886: {Metalloendopeptidases (3.4.24), e.g. collagenase}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides a method for treating a subject suffering from tuberculosis which comprises administering to the subject a composition comprising an amount of an inhibitor of a matrix metalloproteinase (MMP) in an amount effective to treat the subject, such that the therapeutic effect of said composition is different than the therapeutic effect attributable to the antibiotic properties of said composition. The present invention also provides a method for reducing or inhibiting destruction of lung extracellular matrix in a subject comprising administering to the subject at risk for such destruction a composition comprising an amount of an inhibitor of a matrix metalloproteinase (MMP) in an amount effective to reduce or inhibit destruction of lung extracellular matrix in the subject.

## Claims

### Claim 1

A method for treating a subject at risk for destruction of lung extracellular matrix comprising administering to the subject a composition comprising an amount of an inhibitor of matrix metalloproteinase-1 (MMP-1) effective to treat the subject, wherein the MMP-1 inhibitor is
a) an antibody which inhibits the binding of a natural ligand of MMP-1 to MMP-1,
b) an antisense molecule which inhibits the expression of MMP-1 in a cell,
c) an RNAi molecule which inhibits the expression of MMP1 in a cell, or
d) cipemastat.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is suffering from tuberculosis.

### Claim 3 (depends on 1)

The method of claim 1, wherein the MMP-1 inhibitor is an antibody which inhibits the binding of a natural ligand of MMP-1 to MMP-1.

### Claim 4 (depends on 1)

The method of claim 1, wherein the MMP-1 inhibitor is an antisense molecule which inhibits the expression of MMP-1 in a cell.

### Claim 5 (depends on 1)

The method of claim 1, wherein the MMP-1 inhibitor is an RNAi molecule which inhibits the expression of MMP-1 in a cell.

### Claim 6 (depends on 1)

The method of claim 1, wherein the MMP-1 inhibitor is cipemastat.